Literature DB >> 27539136

Challenges of treating incidental synchronous bilateral breast cancer with differing tumour biology.

Jonathan Walter Esclovon1, Melissa Ponder1, Nail Aydin1, Subhasis Misra1.   

Abstract

A 59-year-old woman with right breast mass was diagnosed with invasive ductal carcinoma (IDC). Workup consisted of bilateral diagnostic mammogram and ultrasound (US); both showed a right breast mass with normal left breast. Core biopsy showed IDC with estrogen receptor negative (ER-)/progesterone receptor negative (PR-) and HER2/neu positive receptor status. The patient underwent carboplatin-based chemotherapy with Herceptin. The mass completely resolved. The patient desired to proceed with bilateral total mastectomy with right sentinel lymph node biopsy (SLNB). Pathology showed complete resolution of the right-sided breast mass without malignancy in right SLN. Incidentally, IDC was found in the left breast specimen, which was ER+/PR+ and HER 2/neu negative. Tumour board consensus was to obtain a left axilla US with MRI in 6 months if the US was unremarkable. Biologically different synchronous bilateral breast cancer poses a difficult clinical challenge for management due to differing responses to treatment. Use of MRI may be a diagnostic option in women who choose contralateral prophylactic mastectomy. 2016 BMJ Publishing Group Ltd.

Entities:  

Mesh:

Year:  2016        PMID: 27539136      PMCID: PMC5015134          DOI: 10.1136/bcr-2016-216201

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  26 in total

1.  A case-match study comparing unilateral with synchronous bilateral breast cancer outcomes.

Authors:  Alan M Nichol; Rinat Yerushalmi; Scott Tyldesley; Mary Lesperance; Chris D Bajdik; Caroline Speers; Karen A Gelmon; Ivo A Olivotto
Journal:  J Clin Oncol       Date:  2011-11-21       Impact factor: 44.544

2.  Contralateral breast cancer: molecular differentiation between metastasis and second primary cancer.

Authors:  E Janschek; D Kandioler-Eckersberger; C Ludwig; S Kappel; B Wolf; S Taucher; M Rudas; M Gnant; R Jakesz
Journal:  Breast Cancer Res Treat       Date:  2001-05       Impact factor: 4.872

3.  Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.

Authors:  Donald A Berry; Constance Cirrincione; I Craig Henderson; Marc L Citron; Daniel R Budman; Lori J Goldstein; Silvana Martino; Edith A Perez; Hyman B Muss; Larry Norton; Clifford Hudis; Eric P Winer
Journal:  JAMA       Date:  2006-04-12       Impact factor: 56.272

4.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer.

Authors:  Edward H Romond; Edith A Perez; John Bryant; Vera J Suman; Charles E Geyer; Nancy E Davidson; Elizabeth Tan-Chiu; Silvana Martino; Soonmyung Paik; Peter A Kaufman; Sandra M Swain; Thomas M Pisansky; Louis Fehrenbacher; Leila A Kutteh; Victor G Vogel; Daniel W Visscher; Greg Yothers; Robert B Jenkins; Ann M Brown; Shaker R Dakhil; Eleftherios P Mamounas; Wilma L Lingle; Pamela M Klein; James N Ingle; Norman Wolmark
Journal:  N Engl J Med       Date:  2005-10-20       Impact factor: 91.245

5.  Factors influencing survival in bilateral breast cancer.

Authors:  A S Al-Jurf; P R Jochimsen; L F Urdaneta; D H Scott
Journal:  J Surg Oncol       Date:  1981       Impact factor: 3.454

6.  Breast cancer incidence, 1980-2006: combined roles of menopausal hormone therapy, screening mammography, and estrogen receptor status.

Authors:  Andrew G Glass; James V Lacey; J Daniel Carreon; Robert N Hoover
Journal:  J Natl Cancer Inst       Date:  2007-07-24       Impact factor: 13.506

7.  Synchronous Bilateral Breast Cancers.

Authors:  Naveen Padmanabhan; Annapurneswari Subramanyan; Selvi Radhakrishna
Journal:  J Clin Diagn Res       Date:  2015-09-01

8.  HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.

Authors:  R J Pietras; J Arboleda; D M Reese; N Wongvipat; M D Pegram; L Ramos; C M Gorman; M G Parker; M X Sliwkowski; D J Slamon
Journal:  Oncogene       Date:  1995-06-15       Impact factor: 9.867

9.  Effect of Magnetic Resonance Imaging on Breast Conservation Therapy versus Mastectomy: A Review of the Literature.

Authors:  Thomas J Painter; Peter J Dipasco; Subhasis Misra; Eli Avisar
Journal:  Int J Surg Oncol       Date:  2011-04-19

10.  A case of synchronous bilateral breast cancer with different pathological responses to neoadjuvant chemotherapy with different biological character.

Authors:  Mitsuhiro Hayashi; Yutaka Yamamoto; Noboru Takata; Hirotaka Iwase
Journal:  Springerplus       Date:  2013-06-21
View more
  1 in total

1.  Synchronous and Metachronous Metastatic Breast Cancer, with Different Histology and Opposite Immunophenotype, Treated with Combination of Chemotherapy, Anti-Her2, and Endocrine Therapy: A Case Report.

Authors:  Giacomina Megaro; Luigi Rossi; Serena Ceddia; Marsela Sinjari; Adele Mannino; Elisa Gozzi; Antonella Cosimati; Martina Brandi; Victoria Bitca; Ilaria Toscani; Giuseppe Cimino; Silverio Tomao
Journal:  Case Rep Oncol       Date:  2020-05-13
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.